Cargando…

Long-Term Survival of FOLFIRINOX +toripalimab in a Patient with Metastatic Pancreatic Ductal Adenocarcinoma: A Case Report

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most fatal diseases, with its morbidity and mortality showing an upward trend. The application of monotonous immune checkpoint inhibitor (ICI) in PDAC comes to a disappointing endpoint, despite of its great advancements achieved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Ting, Gao, Chen, Luo, Yiyang, Ye, Zixiang, Wang, Binbin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9423048/ https://www.ncbi.nlm.nih.gov/pubmed/36046467 http://dx.doi.org/10.2147/OTT.S369772

Ejemplares similares

Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma
por: Shui, Lin, et al.
Publicado: (2020)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
por: Klein-Brill, Avital, et al.
Publicado: (2022)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Effects of neoadjuvant FOLFIRINOX and gemcitabine-based chemotherapy on cancer cell survival and death in patients with pancreatic ductal adenocarcinoma
por: Xie, Li, et al.
Publicado: (2019)

Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX
por: Lee, So Heun, et al.
Publicado: (2023)

Long-term Disease-free Survival Following Combination Multi-visceral and Metastatic Resection with Neoadjuvant FOLFIRINOX for Pancreatic Adenocarcinoma: A Case Report
por: Sodergren, Mikael, et al.
Publicado: (2015)

Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report
por: He, Jianping, et al.
Publicado: (2023)

Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment
por: Vuijk, F. A., et al.
Publicado: (2020)

Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Farshadi, Elham Aida, et al.
Publicado: (2021)

Induction Chemotherapy With FOLFIRINOX Followed by Chemoradiation With Gemcitabine in Patients With Borderline-Resectable Pancreatic Ductal Adenocarcinoma
por: Acuna-Villaorduna, Ana, et al.
Publicado: (2022)

Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
por: Mortier, Victor, et al.
Publicado: (2022)

Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?
por: Gall, Tamara M.H., et al.
Publicado: (2019)

Genetic Alterations Predict Long-Term Survival in Ductal Adenocarcinoma of the Pancreatic Head
por: Safi, Sami-Alexander, et al.
Publicado: (2022)

Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis
por: Franck, Caspar, et al.
Publicado: (2019)

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
por: Park, Ji Hoon, et al.
Publicado: (2022)

Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy
por: Tong, Yi Tat, et al.
Publicado: (2023)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
por: Wang, Yi, et al.
Publicado: (2018)

Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis
por: Ramaswamy, Anant, et al.
Publicado: (2023)

SMAD4 Positive Pancreatic Ductal Adenocarcinomas Are Associated with Better Outcomes in Patients Receiving FOLFIRINOX-Based Neoadjuvant Therapy
por: Racu, Marie-Lucie, et al.
Publicado: (2023)

Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma
por: Yoon, Kyoung Won, et al.
Publicado: (2011)

Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
por: Lin, Jingrong, et al.
Publicado: (2020)

Prognostic nomograms for predicting overall survival and cancer-specific survival in patients with angiosarcoma, a SEER population-based study
por: Jiang, Ting, et al.
Publicado: (2022)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI
por: Nikolaou, Christos, et al.
Publicado: (2015)

The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis
por: Zhang, Beilei, et al.
Publicado: (2021)

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy
por: Kaissis, Georgios, et al.
Publicado: (2019)

Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort
por: Portal, Alix, et al.
Publicado: (2015)

FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma
por: Vary, Antonin, et al.
Publicado: (2021)

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes
por: O'Reilly, Eileen M., et al.
Publicado: (2020)

Pretreatment platelet to lymphocyte ratio is predictive of overall survival in metastatic pancreatic ductal adenocarcinoma
por: Li, Wanwan, et al.
Publicado: (2019)

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer
por: Chen, Kuei-Ting, et al.
Publicado: (2023)

Oral mycobiota and pancreatic ductal adenocarcinoma
por: Wei, Ailin, et al.
Publicado: (2022)

Impact of Sarcopenia on Survival in Patients Treated with FOLFIRINOX in a First-Line Setting for Metastatic Pancreatic Carcinoma
por: Lellouche, Lisa, et al.
Publicado: (2023)

The hepatic pre-metastatic niche in pancreatic ductal adenocarcinoma
por: Houg, Demi S., et al.
Publicado: (2018)

Applied precision medicine in metastatic pancreatic ductal adenocarcinoma
por: Taghizadeh, Hossein, et al.
Publicado: (2020)

Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX?
por: Fernandes, Gustavo dos Santos, et al.
Publicado: (2019)

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer
por: Han, Sung Yong, et al.
Publicado: (2020)

Gender Differences in Patients with Metastatic Pancreatic Cancer Who Received FOLFIRINOX
por: Kim, Jinkook, et al.
Publicado: (2021)

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_64m2bv2lfjin8e9cnuhuajlinl